[Federal Register Volume 69, Number 191 (Monday, October 4, 2004)]
[Rules and Regulations]
[Pages 59131-59132]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-22182]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520


Oral Dosage Form New Animal Drugs; Ivermectin Paste

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of a supplemental new animal drug 
application (NADA) filed by Merial Ltd. The supplemental NADA provides 
revised labeling for ivermectin oral paste used in horses.

DATES: This rule is effective October 4, 2004.

FOR FURTHER INFORMATION CONTACT: Martine Hartogensis, Center for 
Veterinary Medicine (HFV-216), Food and Drug Administration, 7519 
Standish Pl., Rockville, MD 20855, 301-827-7815, e-mail: 
<a href="/cdn-cgi/l/email-protection#84e9e5f6f0edeae1aaece5f6f0ebe3e1eaf7edf7c4e2e0e5aae3ebf2"><span class="__cf_email__" data-cfemail="fb969a898f92959ed5939a898f949c9e95889288bb9d9f9ad59c948d">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: Merial Ltd., 3239 Satellite Blvd., Bldg. 
500, Duluth, GA 30096-4640, filed a supplement to NADA 134-314 for 
EQVALAN (ivermectin 1.87 percent) Paste for Horses. The supplemental 
application provides for revisions to the labeled indications. 
Specifically, under the sub-heading ``Small Strongyles,'' the labeling 
has been revised to separate the listing of adult species from the 
fourth-stage larvae. The supplemental NADA is approved as of August 9, 
2004, and 21 CFR 520.1192 is amended to reflect the approval. The basis 
of approval is discussed in the freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    The agency has determined under 21 CFR 25.33(d)(1) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 520

    Animal drugs.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.
0
2. Section 520.1192 is amended by revising paragraph (e)(1) to read as 
follows:

[[Page 59132]]

Sec.  520.1192  Ivermectin paste.

* * * * *
    (e) Conditions of use--(1) Horses--(i) Amount. 200 micrograms per 
kilogram (91 micrograms per pound) of body weight.
    (ii) Indications for use. For treatment and control of:
    (A) Large Strongyles (adults): Strongylus vulgaris (also early 
forms in blood vessels), S. edentatus (also tissue stages), S. equinus, 
Triodontophorus spp. including T. brevicauda and T. serratus, and 
Craterostomum acuticaudatum; Small Strongyles (adults, including those 
resistant to some benzimidazole class compounds): Coronocyclus spp. 
including C. coronatus, C. labiatus, and C. labratus, Cyathostomum spp. 
including C. catinatum and C. pateratum, Cylicocyclus spp. including C. 
insigne, C. leptostomum, C. nassatus, and C. brevicapsulatus, 
Cylicodontophorus spp., Cylicostephanus spp., including C. calicatus, 
C. goldi, C. longibursatus, and C. minutus, and Petrovinema poculatum; 
Small Strongyles (fourth-stage larvae); Pinworms (adults and fourth 
stage larvae): Oxyuris equi; Ascarids (adults and third- and fourth-
stage larvae): Parascaris equorum; Hairworms (adults): Trichostrongylus 
axei; Large mouth Stomach Worms (adults), Habronema muscae; Bots (oral 
and gastric stages): Gasterophilus spp. including G. intestinalis and 
G. nasalis; Lungworms (adults and fourth-stage larvae): Dictyocaulus 
arnfieldi; Intestinal Threadworms (adults): Strongyloides 
westeri;Summer Sores caused by Habronema and Draschia spp. cutaneous 
third-stage larvae; Dermatitis caused by neck threadworm microfilariae, 
Onchocerca sp.
    (B) Large Strongyles (adult) (Strongylus equinus), (adult and 
arterial larval stages) (Strongylus vulgaris), (adult and migrating 
tissue stages) (Strongylus edentatus), (adult) (Triodontophorus spp.); 
Small Strongyles, including those resistant to some benzimidazole class 
compounds (adult and fourth-stage larvae) (Cyathostomum spp., 
Cylicocyclus spp., Cylicodontophorus spp., Cylicostephanus spp.); 
Pinworms (adult and fourth-stage larvae) (Oxyuris equi); Ascarids 
(third- and fourth-stage larvae and adults) (Parascaris equorum); 
hairworms (adult) (Trichostrongylus axei); Large mouth Stomach Worms 
(adult) (Habronema muscae); Stomach Bots (oral and gastric stages) 
(Gastrophilus spp.); Lungworms (adults and fourth-stage larvae) 
(Dictyocaulus arnfieldi); Intestinal Threadworms (adults) 
(Strongyloides westeri); Summer Sores caused by Habronema and Draschia 
spp. cutaneous third-stage larvae; and Dermatitis caused by neck 
threadworm microfilariae (Onchocerca sp.).
    (iii) Limitations. For oral use only. Do not use in horses intended 
for human consumption.
* * * * *

    Dated: September 14, 2004.
Daniel G. McChesney,
Director, Office of Surveillance and Compliance, Center for Veterinary 
Medicine.
[FR Doc. 04-22182 Filed 10-1-04; 8:45 am]
BILLING CODE 4160-01-S


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>